7:08 PM
 | 
Feb 02, 2016
 |  BC Extra  |  Financial News

Spero closes $30M series B round

Anti-infective play Spero Therapeutics LLC (Cambridge, Mass.) secured $30 million in a tranched series B round from existing investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, the Kraft Group and...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >